Published in Diabetes Care on April 01, 1992
How to be Safe With Alcoholic Drinks in Diabetes (BEER) | NCT02518022
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Arch Dermatol (1998) 2.22
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group. AIDS (1997) 2.21
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis (2000) 1.78
Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1999) 1.62
HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. Ann Oncol (1991) 1.44
Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med (2002) 1.44
[Seroprevalence of viral hepatitis C in patients with human immunodeficiency virus infection]. Presse Med (1992) 1.42
Surveillance of heterosexually acquired HIV infection and AIDS. Lancet (1995) 1.40
Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients. J Clin Microbiol (1995) 1.39
Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med (2007) 1.36
Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med (2005) 1.32
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.25
[Letter: Hypoglycemia after perhexiline maleate]. Nouv Presse Med (1975) 1.21
Prevalence and underestimation of pain in HIV-infected patients by physicians: a cross-sectional study in a day care hospital. AIDS (1999) 1.21
[Hematologic and immunologic manifestations of primary cytomegalovirus infections in non-immunocompromised hospitalized adults]. Rev Med Interne (2000) 1.21
Tuberculosis in patients infected with human immunodeficiency virus 1. A retrospective multicentre study of 123 cases in France. The Groupe des Infectiologues du Sud de la France. Q J Med (1992) 1.20
Determinants of delayed diagnosis of HIV infection in France, 1993-1995. AIDS (1998) 1.18
Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. The Groupe d'Epidémiologie Clinique Du SIDA en Aquitaine. Obstet Gynecol (1995) 1.17
Attempted suicide by insulin injection treated with artificial pancreas. Br Med J (Clin Res Ed) (1983) 1.15
Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med (2005) 1.15
Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol (1997) 1.14
Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med (2004) 1.13
Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med (2001) 1.12
Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine. Clin Infect Dis (2000) 1.09
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med (2009) 1.08
Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus (1999) 1.07
Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother (1991) 1.06
Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: is HHV-8 subtype A responsible for more agressive tumors? J Infect Dis (1998) 1.03
Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. Epidemiol Infect (2006) 1.02
Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients. AIDS (1996) 1.02
Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr (2001) 1.01
Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J Infect Dis (1999) 0.97
Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability. AIDS Care (2011) 0.97
[Anterior uveitis and cidofovir]. J Fr Ophtalmol (2001) 0.96
Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. AIDS Res Hum Retroviruses (1997) 0.96
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother (2000) 0.96
Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism (1985) 0.94
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Control Clin Trials (1998) 0.93
The influence of Guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res (1989) 0.93
Increases in CD3+CD4-CD8- T lymphocytes in AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. J Infect Dis (1996) 0.92
JC virus remains latent in peripheral blood B lymphocytes but replicates actively in urine from AIDS patients. J Infect Dis (1998) 0.91
Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis (2003) 0.90
Herpes zoster and human immunodeficiency virus infection: a cohort study of 101 coinfected patients. Groupe d'Epidémiologie clinique du SIDA en aquitaine. J Infect Dis (1993) 0.90
Foscarnet decreases HIV-1 plasma load. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.90
Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy. Clin Immunol (2001) 0.90
[Recurrent peritonitis caused by Stomatococcus mucilanoginosus in a patient treated with continuous ambulatory peritoneal dialysis]. Presse Med (1985) 0.89
Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol (2002) 0.88
Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract (1989) 0.88
HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Med (2006) 0.88
Cervical dysplasia and human immunodeficiency virus infection in women: prevalence and associated factors. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GESCA). Eur J Obstet Gynecol Reprod Biol (1998) 0.87
Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med (2004) 0.87
Influence of glycaemic normalisation by an artificial pancreas on phagocytic and bactericidal functions of granulocytes in insulin dependent diabetic patients. J Clin Pathol (1984) 0.87
Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort. Int J STD AIDS (2011) 0.86
[Causes of death among HIV infected adults in French Guyana and the French West Indies in the era of highly active antiretroviral therapy (HAART)]. Med Mal Infect (2004) 0.86
Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. J Viral Hepat (2011) 0.85
Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985-1991. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. J Natl Cancer Inst (1992) 0.85
A low-protein diet improves insulin sensitivity of endogenous glucose production in predialytic uremic patients. Am J Clin Nutr (1997) 0.83
Circulating autoantibodies directed against conjugated fatty acids in sera of HIV-1-infected patients. Clin Exp Immunol (1994) 0.83
Clinical prediction of lower limb deep vein thrombosis in symptomatic hospitalized patients. Thromb Haemost (2001) 0.83
[Aortic aneurysms due to Yersinia enterocolitica: three new cases and a review of the literature]. J Mal Vasc (1996) 0.83
Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS (2001) 0.83
Prosthetic valve endocarditis: diagnosis and prognosis. Eur Heart J (1984) 0.82
[Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic ant therapeutic difficulties]. Rev Med Interne (2006) 0.82
Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis. J Clin Pharmacol (1993) 0.82
Effects of red wine, tannic acid, or ethanol on glucose tolerance in non-insulin-dependent diabetic patients and on starch digestibility in vitro. Metabolism (1999) 0.82
Cefotaxime in the treatment of septicaemia and endocarditis. J Antimicrob Chemother (1980) 0.82
Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient. J Infect (2000) 0.81
Anthrax meningitis. Report of two cases with autopsies. Acta Neuropathol (1976) 0.81
A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis (2002) 0.81
Sarcoidosis-associated hepatitis C virus infection. Dig Dis Sci (2002) 0.81
Mycoplasmas in HIV-1 seropositive patients. Lancet (1993) 0.80
[Isolated involvement of the trigeminal nerve of sarcoidosis origin]. Rev Neurol (Paris) (1997) 0.80
IgE serum level: a prognostic marker for AIDS in HIV-infected adults? J Allergy Clin Immunol (1998) 0.80
Agarose encapsulation of islets of Langerhans: reduced toxicity in vitro. J Microencapsul (1989) 0.80
Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. Vaccine (2009) 0.80
[Hemorrhagic fever with renal syndrome: a case with jaundice]. Gastroenterol Clin Biol (1986) 0.80
Rhabdomyolysis and Salmonella enteritidis infection. Eur J Clin Microbiol Infect Dis (2000) 0.80
Clinical and laboratory findings of cytomegalovirus infection in 115 hospitalized non-immunocompromised adults. Ann Med Interne (Paris) (2001) 0.79
Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. Epidemiol Infect (2005) 0.79
An enlarged subpopulation of T lymphocytes bearing two distinct gammadelta TCR in an HIV-positive patient. Int Immunol (1999) 0.79
Emphysematous cystitis. Diabetes Metab (2004) 0.79